Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: An intention to mobilize and transplant analysis

European Journal of Haematology

Volumn 72, Issue 1, 2004, Pages 10-17

  Olivieri, Attilio ^a,c   Brunori, Marino ^a   Capelli, Debora ^a   Montanari, Mauro ^a   Massidda, Danilo ^a   Gini, Guido ^a   Lucesole, Moira ^a   Poloni, Antonella ^a   Offidani, Massimo ^a   Candela, Marco ^a   Centurioni, Riccardo ^b   Leoni, Pietro ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b Civitanova Marche Hospital   (Italy)

^c Ospedale Regionale Torrette   (Italy)

Author keywords

Autologous transplant; DHAP; Mobilization; Non Hodgkin lymphoma; Relapse

Indexed keywords

CISPLATIN; CYTARABINE; DEXAMETHASONE; FLUDARABINE;

ACUTE TOXICITY; ADULT; AGED; ARTICLE; AUTOGRAFT; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NONHODGKIN LYMPHOMA; OUTPATIENT; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; SALVAGE THERAPY; SEIZURE; TOXICITY; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYTARABINE; DEXAMETHASONE; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PATIENT SELECTION; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT FAILURE;

EID: 10744223888     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0902-4441.2004.00171.x     Document Type: Article

References (26)

1. SCHMITZ N, PFISTNER B, SEXTRO M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359:2065-2071.
2. FREEDMAN AS, RITZ J, NEUBERG D, et al. Autologous bone marrow transplantation in 69 patients with history of low-grade B-cell non Hodgkin's lymphoma. Blood 1991;77:2524-2529.
3. PHILIP T, GUGLIELMI C, HAGENBEEK A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapsed of chemotherapy-sensitive non-Hodgkin Lymphoma. N Engl J Med 1995;333:1540-1545.
4. LINCH DC, WINFIELD D, GOLDSTONE AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993;341:1051-1054.
5. VELASQUEZ WS, MCLAUGHLIN P, TUCKER S, HAGEMEISTER FB, SWAN F, RODRIGUEZ MA, ROMAGUERA J, RUBENSTEIN E, CABANILLAS F. ESHAP: an effective chemotherapy regimen in refractory or relapsed lymphoma: a 4 years follow-up study. J Clin Oncol 1993;12:1169-1176.
6. AURLIEN E, HOLTE H, KVALOY S, JAKOBSEN E, RUSTEN LS, KVALHEIM G. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients. Eur J Haematol Suppl 2001;64:14-20.
7. VELASQUEZ WS, CABANILLAS F, SALVADOR P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexametasone (DHAP). Blood 1988;71:117-122.
8. TARELLA C, CARACCIOLO D, CORRADINI P, ZALLIO F, LADETTO M, CUTTICA A, ROSSI G, NOVERO D, GAVAROTTI P, PILERI A. Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft. Leukemia 2000; 14:740-747.
9. VELLENGA E, VAN AGTHOVEN M, CROOCKEWIT AJ, et al. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study. Br J Haematol 2001;114:319-326.
10. VOSE JM, ARMITAGE JO, BIERMAN PJ, et al. Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing autologous bone marrow transplantation. Am J Med 1989;87:285-288.
11. OLIVIERI A, OFFIDANI M, CINIERO L, CANTORI I, OMBROSI L, MANCINI S, MASIA MC, SCALARI P, LEONI P. DHAP regimen plus G-CSF as salvage therapy and priming for blood progenitor cell collection in patients with poor prognosis lymphoma. Bone Marrow Transplant 1995;16:85-93.
12. MONTANARI M, CAPELLI D, POLONI A, et al. Long-term hematologic reconstitution after autologous peripheral blood progenitor cell transplantation: a comparison between controlled-rate freezing and uncontrolled-rate freezing at -80°C. Transfusion 2003;43:42-49.
13. OLIVIERI A, MONTANARI M, MANCINI S, et al. Hemopoietic progenitors cryopreservation: comparison between controlled (crf) and uncontrolled-rate freezing with different DMSO concentration. Atti V congresso SIES, Siena 23-25 Settembre, 1998.
14. ELLIOTT TS, FAROQUI MH, ARMSTRONG RF, HANSON GC. Guidelines for good practice in central venous catheterization. Hospital Infection Society and the Research Unit of the Royal College of Physicians. J Hosp Infect 1994;28: 163-176.
15. BRUNDAGE MD, PATER JL, ZEE B. Assessing the reliability of two toxicity scales: implications for interpreting toxicity data. J Natl Cancer Inst 1993;85:1138-1148.
16. VOSE JM, ZHANG MJ, ROWLINGS PA, et al. Autologous Blood and Marrow Transplant Registry Lymphoma Working Committee. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001;19: 406-413.
17. BIERMAN PJ, VOSE JM, ANDERSON JR, BISHOP MR, KESSINGER A, ARMITAGE JO. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 1997;15:445-450.
18. SWEETENHAM JW, CARELLA AM, TAGHIPOUR G, CUNNINGHAM D, MARCUS R, DELLA VOLPE A, LINCH DC, SCHMITZ N, GOLDSTONE AH. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol 1999;17: 3101-3109.
19. MOSKOWITZ CH, GLASSMAN JR, WUEST D, MASLAK P, REICH L, GUCCIARDO A, COADY-LYONS N, ZELENETZ AD, NIMER SD. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 1998;4:311-316.
20. KETTERER N, SALLES G, MOULLET I, et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998;103:235-242.
21. BLAY J, GOMEZ F, SEBBAN C, BACHELOT T, BIRON P, GUGLIELMI C, HAGENBEEK A, SOMERS R, CHAUVIN F, PHILIP T. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood 1998;92:3562-3568.
22. MOSKOWITZ CH, BERTINO JR, GLASSMAN JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3776-3785.
23. MOSKOWITZ CH, NIMER SD, ZELENETZ AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97:616-623.
24. GIANNI AM, SIENA S, BREGNI M, LOMBARDI F, GANDOLA L, DI NICOLA M, MAGNI M, PECCATORI F, VALAGUSSA P, BONADONNA G. High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease - a 6-year update. Ann Oncol 1993;4:889-891.
25. BALZAROTTI M, GRISANTI S, GRANZOW K, et al. Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine. Semin Oncol 1999;26:S66-S71.
26. OLIVIERI A, OFFIDANI M, CANTORI I, CINIERO L, OMBROSI L, MASIA MC, BRUNORI M, MONTRONI M, LEONI P. Addition of erythropoietin to granulocyte colony-stimulating factor after priming chemotherapy enhances hemopoietic progenitor mobilization. Bone Marrow Transplant 1995;16:765-770.